Skip to main content
Mirum Pharmaceuticals, Inc. logo

Mirum Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · MIRM ISIN · US6047491013 LEI · 254900YZKR40F7F27K81 US Manufacturing
Filings indexed 584 across all filing types
Latest filing 2026-05-04 Regulatory Filings
Country US United States of America
Listing US MIRM

About Mirum Pharmaceuticals, Inc.

https://mirumpharma.com/

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases, with a primary focus on debilitating liver conditions affecting both children and adults. The company's lead commercial product is LIVMARLI® (maralixibat), an oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome. Mirum's clinical pipeline is advancing other potential treatments, including volixibat, for various rare cholestatic liver diseases. The company's mission is to transform the treatment landscape for patients with significant unmet medical needs by advancing its scientific programs from discovery through commercialization.

Recent filings

Filing Released Lang Actions
8-K - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
Regulatory Filings
2026-05-04 English
8-K - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
Regulatory Filings
2026-04-27 English
ARS - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
Annual Report
2026-04-24 English
8-K/A - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)
Regulatory Filings
2026-04-08 English
SCHEDULE 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)
Major Shareholding Notification
2026-03-27 English
4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)
Director's Dealing
2026-03-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.